Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $72.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target hoisted by Oppenheimer from $65.00 to $72.00 in a report issued on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

Separately, The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $55.60.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $48.11 on Wednesday. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The business has a fifty day simple moving average of $50.92 and a two-hundred day simple moving average of $38.73. The company has a market capitalization of $1.84 billion, a P/E ratio of -12.63 and a beta of 1.02.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after purchasing an additional 698,712 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after acquiring an additional 420,057 shares during the period. Millennium Management LLC grew its stake in Tarsus Pharmaceuticals by 1,259.3% during the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after acquiring an additional 322,942 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $10,587,000. Finally, Vestal Point Capital LP bought a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $7,565,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.